Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression
Stopped early · Phase 1
Conditions studied: Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer, Bladder Cancer
In brief
This study evaluated ADCT-502 in participants with Advanced Solid Tumors with HER2 Expression. Participants participated in a dose-escalation phase (Part 1) and were due to participate in the dose expansion phase (Part 2). In Part 2, patients were due to receive the dose level identified in Part 1, but the study was terminated prior to the beginning of Part 2.
Key facts
- Study ID
- NCT03125200
- Run by
- ADC Therapeutics S.A.
- People needed
- 21
- Starts
- 2017-05-18
- Expected to finish
- 2018-04-05
- Last updated by the study team
- 2021-02-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford Cancer Center — Palo Alto, California, United States
- Roswell Park Cancer Institute — Buffalo, New York, United States
- Memorial Sloan Kettering Memorial Hospital — New York, New York, United States
- South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas, United States
- Medical Oncology Clinic - Institut Jules Bordet — Brussels, Belgium
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.